Review article · 2019 · Open access

Gemcitabine Combination Nano Therapies for Pancreatic Cancer

Kamalika Samanta, Saini Setua, Sonam Kumari, Meena Jaggi, Murali Mohan Yallapu, Subhash Chandra Chauhan

Pharmaceutics, 11(11), 574 · Published 4 November 2019 · DOI 10.3390/pharmaceutics11110574

Open PDFView at the publisherCite this paper

In brief

“Gemcitabine Combination Nano Therapies for Pancreatic Cancer” is a 2019 review article by Kamalika Samanta and 5 co-authors, published in Pharmaceutics. OpenAlex counts 109 citations as of 21 November 2026, which puts it in the top 1% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmaceutics.

Citations
109
Most cited in
2024 (21)
Field-weighted impact
0.69
References
101
Authors
6

Abstract

Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination therapies often induce severe systemic toxicities. Thus, developing strategies to deliver a combination of chemotherapeutic agents more securely to patients is needed. Nanoparticle-mediated delivery can offer to load a cocktail of drugs, increase stability and availability, on-demand and tumor-specific delivery while minimizing chemotherapy-associated adverse effects. This review discusses the available drugs being co-administered with GEM and the limitations associated during the process of co-administration. This review also helps in providing knowledge of the significant number of delivery platforms being used to overcome problems related to gemcitabine-based co-delivery of other chemotherapeutic drugs, thereby focusing on how nanocarriers have been fabricated, considering the modes of action, targeting receptors, pharmacology of chemo drugs incorporated with GEM, and the differences in the physiological environment where the targeting is to be done. This review also documents the focus on novel mucin-targeted nanotechnology which is under development for pancreatic cancer therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Samanta, K., Setua, S., Kumari, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2019). Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics, 11(11), 574. https://doi.org/10.3390/pharmaceutics11110574

MLA 9

Samanta, Kamalika, et al. “Gemcitabine Combination Nano Therapies for Pancreatic Cancer.” Pharmaceutics, vol. 11, no. 11, 2019, p. 574. https://doi.org/10.3390/pharmaceutics11110574.

Chicago

Samanta, Kamalika, Saini Setua, Sonam Kumari, Meena Jaggi, Murali Mohan Yallapu, and Subhash Chandra Chauhan. 2019. “Gemcitabine Combination Nano Therapies for Pancreatic Cancer.” Pharmaceutics 11 (11): 574. https://doi.org/10.3390/pharmaceutics11110574.

Harvard

Samanta, K. et al. (2019) ‘Gemcitabine Combination Nano Therapies for Pancreatic Cancer’, Pharmaceutics, 11(11), p. 574. doi:10.3390/pharmaceutics11110574.

IEEE

K. Samanta, S. Setua, S. Kumari, M. Jaggi, M. M. Yallapu, and S. C. Chauhan, “Gemcitabine Combination Nano Therapies for Pancreatic Cancer,” Pharmaceutics, vol. 11, no. 11, p. 574, 2019, doi: 10.3390/pharmaceutics11110574.

BibTeX

@article{samanta2019gemcitabine,
  title     = {{Gemcitabine Combination Nano Therapies for Pancreatic Cancer}},
  author    = {Samanta, Kamalika and Setua, Saini and Kumari, Sonam and Jaggi, Meena and Yallapu, Murali Mohan and Chauhan, Subhash Chandra},
  journal   = {Pharmaceutics},
  year      = {2019},
  volume    = {11},
  number    = {11},
  pages     = {574},
  doi       = {10.3390/pharmaceutics11110574},
  url       = {https://doi.org/10.3390/pharmaceutics11110574}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20201717
20211414
20221414
20231111
20242121
20252121
20261111

Its field-weighted citation impact is 0.69: it has been cited 0.69 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • gemcitabine
  • pancreatic cancer
  • combination chemotherapy
  • nanoparticle drug delivery
  • nanocarriers
  • chemoresistance
  • tumor-targeted delivery
  • drug co-delivery

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Samanta, K., Setua, S., Kumari, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2019). Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics, 11(11), 574. https://doi.org/10.3390/pharmaceutics11110574

How many times has this paper been cited?

109 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pharmaceutics: sign in and open the PDF from this page.

Who wrote this paper?

Kamalika Samanta, Saini Setua, Sonam Kumari, Meena Jaggi, Murali Mohan Yallapu, Subhash Chandra Chauhan.

What is the DOI of this paper?

10.3390/pharmaceutics11110574, permanently at https://doi.org/10.3390/pharmaceutics11110574. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.